公开(公告)号：US20230270753A1

公开(公告)日：2023-08-31

申请号：US18015439

申请日：2021-07-09

申请人： AGENEBIO, INC.

发明人： Michela Gallagher ,  Sharon Rosenzweig-Lipson

IPC分类号： A61K31/5517 ,  A61P25/28 ,  A61K9/00 ,  A61K31/4015

CPC分类号： A61K31/5517 ,  A61P25/28 ,  A61K9/0053 ,  A61K31/4015 ,  C07B2200/13

摘要： This disclosure relates to methods, uses, combinations, pharmaceutical compositions, combinations for use, and pharmaceutical compositions for use useful for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), in combination with GABAA α5 receptor agonists, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism, compulsive behavior, and substance addiction. Further, the disclosure relates to methods, uses, combinations, pharmaceutical compositions, combinations for use, and pharmaceutical compositions for use useful for treating cognitive impairment associated with brain cancer or for treating brain cancer itself in a subject in need thereof. Additionally, the disclosure relates to methods, uses, combinations, pharmaceutical compositions, combinations for use, and pharmaceutical compositions for use useful for treating Parkinson's disease psychosis in a subject in need thereof.

公开(公告)号：US20230134844A1

公开(公告)日：2023-05-04

申请号：US17902374

申请日：2022-09-02

申请人： AGENEBIO, INC.

发明人： Belew Mekonnen ,  John A. Butera ,  Jianxing Huang ,  Hemantbhai Patel

IPC分类号： C07D487/14

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

公开(公告)号：US11160785B2

公开(公告)日：2021-11-02

申请号：US14776378

申请日：2014-03-14

申请人： AgeneBio, Inc.

发明人： Gardiner Smith

IPC分类号： A61K31/4015 ,  A61K31/445 ,  A61K31/27 ,  A61K31/662 ,  A61K31/55

摘要： The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

公开(公告)号：US20180140555A1

公开(公告)日：2018-05-24

申请号：US15574824

申请日：2016-05-20

申请人： AgeneBio, Inc.

发明人： Michela Gallagher ,  Sharon Rosenzweig-Lipson ,  Elsie Melsopp ,  Jack Lawrence James

IPC分类号： A61K9/20 ,  A61K31/4015 ,  A61K9/00

CPC分类号： A61K9/2054 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K31/4015

摘要： This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof.

公开(公告)号：US20170022208A1

公开(公告)日：2017-01-26

申请号：US15104494

申请日：2014-12-19

申请人： AGENEBIO, INC.

发明人： Belew MEKONNEN ,  John A. BUTERA ,  Jianxing HUANG

IPC分类号： C07D487/14 ,  A61K45/06 ,  A61K31/5517 ,  A61K31/551

CPC分类号： C07D487/14 ,  A61K31/551 ,  A61K31/5517 ,  A61K45/06

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

摘要翻译： 本发明涉及苯并二氮杂衍生物，包含治疗有效量的那些苯并二氮杂衍生物的组合物和使用这些衍生物或组合物治疗与中枢神经系统（CNS）病症相关的认知障碍的方法。 特别地，本发明涉及在本文所述的含有α5的GABA A受体激动剂（例如，含有α5的GABA A受体阳性变构调节剂）在治疗有需要的受试者中与中枢神经系统（CNS）紊乱相关的认知障碍 包括但不限于有年龄相关认知障碍或轻度认知障碍（MCI），遗忘MCI（aMCI），年龄相关记忆障碍（AAMI），年龄相关认知衰退（ARCD） ），痴呆，阿尔茨海默病（AD），前驱性AD，创伤后应激障碍（PTSD），精神分裂症，双相情感障碍，肌萎缩性侧索硬化（ALS），癌症治疗相关认知障碍，精神发育迟滞，帕金森病（PD） 孤独症谱系障碍，脆性X病症，Rett综合征，强迫行为和物质成瘾。

公开(公告)号：US11312721B2

公开(公告)日：2022-04-26

申请号：US17028917

申请日：2020-09-22

申请人： AGENEBIO, INC.

发明人： Belew Mekonnen ,  John A. Butera ,  Jianxing Huang

IPC分类号： C07D487/12 ,  C07D487/14 ,  A61K31/5513 ,  A61K45/06 ,  A61K31/13 ,  A61K31/551 ,  A61K31/496 ,  A61K31/445 ,  A61K31/55 ,  A61K31/27 ,  A61P25/00 ,  A61K31/5517

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

公开(公告)号：US20210253588A1

公开(公告)日：2021-08-19

申请号：US16471237

申请日：2017-12-20

申请人： AGENEBIO, INC.

发明人： Belew Mekonnen ,  John A. Butera ,  Jianxing Huang

IPC分类号： C07D487/14

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-C containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

公开(公告)号：US20200048268A1

公开(公告)日：2020-02-13

申请号：US16445854

申请日：2019-06-19

申请人： AGENEBIO, INC.

发明人： Belew Mekonnen ,  John A. Butera ,  Jianxing Huang ,  Hemantbhai Patel ,  Qin Jiang ,  Robert Jason Herr ,  Emily Elizabeth Freeman ,  Nicholas James Mayhew

IPC分类号： C07D487/14 ,  A61P25/16 ,  A61P25/28 ,  A61P25/18

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

公开(公告)号：US20190284196A1

公开(公告)日：2019-09-19

申请号：US16428394

申请日：2019-05-31

申请人： AGENEBIO, INC.

发明人： Belew Mekonnen ,  John A. Butera ,  Jianxing Huang

IPC分类号： C07D487/14 ,  A61K45/06 ,  A61K31/551 ,  A61K31/5517

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a a5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

公开(公告)号：US20190055258A1

公开(公告)日：2019-02-21

申请号：US15736697

申请日：2016-06-17

申请人： AgeneBio, Inc.

发明人： Belew Mekonnen ,  John A. Butera ,  Jianxing Huang

IPC分类号： C07D487/14 ,  A61K31/551 ,  A61K31/5517 ,  A61K45/06 ,  A61K31/13 ,  A61P25/00

CPC分类号： C07D487/14 ,  A61K31/13 ,  A61K31/27 ,  A61K31/445 ,  A61K31/496 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5517 ,  A61K45/06 ,  A61P25/00 ,  A61K2300/00

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.